title: Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis.
authors.forename: M A
authors.initials: MA
authors.lastname: Elliott
authors.forename: A
authors.initials: A
authors.lastname: Pardanani
authors.forename: C Y
authors.initials: CY
authors.lastname: Li
authors.forename: A
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D000328:Adult; D001549:Benzamides; D001854:Bone Marrow Cells / Q000276:immunology / Q000473:pathology; D004802:Eosinophilia / Q000150:complications* / Q000276:immunology / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D008297:Male; D008407:Mast Cells / Q000276:immunology* / Q000473:pathology; D034721:Mastocytosis, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate